Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-06-15	36.26 €	+0.18%
26-06-12	36.19 €	+0.72%
26-06-11	35.93 €	+1.41%
26-06-10	35.43 €	-0.25%
26-06-09	35.52 €	-0.95%

Real-time CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

More quotes

Analysis / Opinion

Can Bayer Still Recover?

May 21, 2026 at 04:06 am

Bayer: An assuring quarter towards gradual transformation

May 12, 2026 at 12:06 pm

Roundup: Bayer ordered to pay $2.1bn to an American suffering from cancer

March 24, 2025 at 06:21 am

More analyses

Real-time CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL) Other stock markets 10:39:37 2026-06-15 EDT			5-day change	1st Jan Change
36.26 ^EUR	+0.18%		+2.48%	-33.31%

04:35am	Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity	CI
03:01am	Bayer Gets US FDA Nod for Low-dose MRI Contrast Agent Gadoquatrane	MT

Market Cap	35.55B 41.16B 32.76B 30.67B 57.47B 3,913B 58.36B 387B 151B 1,904B 154B 151B 6,594B	P/E Ratio 2026 *	15.4x	P/E Ratio 2027 *	11.6x
Enterprise Value	67.25B 77.86B 61.97B 58.01B 109B 7,401B 110B 732B 285B 3,602B 292B 286B 12,473B	EV / Sales 2026 *	1.48x	EV / Sales 2027 *	1.37x
Free-Float	100%	Yield 2026 *	0.61%	Yield 2027 *	2.04%

04:35am	Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity	CI
03:01am	Bayer Gets US FDA Nod for Low-dose MRI Contrast Agent Gadoquatrane	MT
02:18am	Berenberg Ups Bayer's Price Target, Estimates; Hold Rating Amid Settlement Uncertainty	MT
06-12	Germany's DAX Index Rallies on Inflation Report, US-Iran Deal Hopes	MT
06-12	Berenberg remains cautious on Bayer amid ongoing US litigation
06-12	BAYER AG : Gets a Neutral rating from Berenberg	ZD
06-12	Berenberg Raises Bayer Price Target to €40.50, Maintains 'Hold' Rating	DP
06-10	Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch	RE
06-10	Bayer's Marketing Authorization Application for Asundexian Gets EU Medicines Agency's Validation	MT
06-09	Bayer Appoints Jost Reinhard as President of Radiology Business Within Bayer's Pharmaceuticals Division, Effective August 1, 2026	CI
06-09	BAYER AG : UBS keeps its Buy rating	ZD
06-08	Bayer Ag Appoints .Jana Marlen Ackermann as Head of Investor Relations, Effective August 1, 2026	CI
06-08	Bayer AG Announces Executive Changes	CI

02:18am	Berenberg Ups Bayer's Price Target, Estimates; Hold Rating Amid Settlement Uncertainty	MT
06-12	Berenberg remains cautious on Bayer amid ongoing US litigation
06-12	BAYER AG : Gets a Neutral rating from Berenberg	ZD
06-12	Berenberg Raises Bayer Price Target to €40.50, Maintains 'Hold' Rating	DP
06-09	BAYER AG : UBS keeps its Buy rating	ZD

Bayer AG Stock CBOE EUROPE EQUITIES - EUROPEAN EQUITIES (NL)

Stocks

BAYNd

DE000BAY0017

Pharmaceuticals

Valuation: Bayer AG

Chart: Bayer AG

Latest news : Bayer AG

Last Transcript: Bayer AG

Analysts' recommendations: Bayer AG

Press Releases: Bayer AG

News in other languages: Bayer AG

Quotes and Performance

Course Extremes

Managers and Directors: Bayer AG

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

06:07am	Bayer : Expands Open Innovation Network in China with New Hub in Shandong Province	PU
02:35am	Bayer : low-dose MRI contrast agent approved in U.S.	PU
02:30am	Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions	BU
06-10	Dr. Jost Reinhard Appointed President of Bayer's Radiology Business	AQ
06-10	Bayer : European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke	PU

06:03am	Bayer : baut Open-Innovation-Netzwerk in China mit neuem Hub in der Provinz Shandong aus
04:49am	Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
03:51am	Bayer voit son Gadoquatrane approuvé aux Etats-Unis
03:30am	Bayern voit son Gadoquatrane approuvé aux Etats-Unis
02:30am	Bayer bekommt US-Zulassung für neues MRT-Kontrastmittel

1 week	-0.22%
Current month	-0.19%
1 month	-6.17%
3 months	-7.43%
6 months	-1.04%
Current year	-2.18%

1 week	34.83	36.68
1 month	32.9	39.46
3 years	18.39	53.79
5 years	18.39	67.99

Manager	Title	Age	Since
William Anderson CEO	Chief Executive Officer	59	2023-05-31
Judith Hartmann DFI	Director of Finance/CFO	57	2026-05-31
Christian Rommel CTO	Chief Tech/Sci/R&D Officer	59	2021-01-31

Director	Title	Age	Since
André van Broich BRD	Director/Board Member	56	2012-03-31
Heinz Georg Webers BRD	Director/Board Member	66	2022-03-31
Heike Hausfeld BRD	Director/Board Member	60	2017-03-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAYER AG	+0.18%	+2.48%	+29.92%	-29.19%	41.16B
ELI LILLY AND COMPANY	-0.46%	-1.67%	+39.93%	+148.94%	1,010B
JOHNSON & JOHNSON	-1.72%	+2.18%	+52.83%	+44.89%	580B
ABBVIE INC.	-2.34%	-0.20%	+16.65%	+63.83%	402B
ROCHE HOLDING AG	-0.20%	0.00%	+21.28%	+19.14%	330B
NOVARTIS AG	-1.11%	+2.93%	+25.33%	+33.65%	281B
ASTRAZENECA PLC	-1.75%	-4.18%	+22.20%	+13.13%	280B
NOVO NORDISK A/S	-0.57%	+5.35%	-42.47%	-48.11%	197B
AMGEN INC.	+0.35%	+2.85%	+20.31%	+55.66%	192B
GILEAD SCIENCES, INC.	-0.07%	-2.80%	+12.34%	+57.61%	156B
Average	-0.91%	+0.84%	+19.83%	+35.95%	380.97B
Weighted average by Cap.	-1.03%	+1.04%	+27.87%	+66.46%

	2026 *	2027 *
Net sales	45.54B 52.73B 41.97B 39.28B 73.62B 5,012B 74.76B 496B 193B 2,439B 198B 194B 8,446B	46.81B 54.2B 43.13B 40.38B 75.67B 5,151B 76.84B 509B 199B 2,507B 203B 199B 8,682B
Net income	2.17B 2.51B 2B 1.87B 3.51B 239B 3.56B 23.63B 9.21B 116B 9.44B 9.23B 403B	3B 3.47B 2.76B 2.58B 4.84B 330B 4.92B 32.6B 12.71B 160B 13.02B 12.74B 556B
Net Debt	31.7B 36.7B 29.21B 27.34B 51.24B 3,488B 52.03B 345B 134B 1,698B 138B 135B 5,879B	28.63B 33.14B 26.38B 24.69B 46.27B 3,150B 46.99B 311B 121B 1,533B 124B 122B 5,309B